Q2 growth, expanded capacity and FY28 revenue and EBITDA targets

Management guided margin improvementOrder pipeline disclosedCFO laid out a debt-reduction roadmapInvestor Communications View source PDF Explain this filing

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.9%Reaction day

₹1556.00

prior close

₹1563.00

announcement price

In-mkt

timing

Nifty Smallcap 250market+0.4%+0.5% vs market

Pharmaceuticals peers, median of 170sector+0.1%+0.8% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Smallcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.3

15m

+0.2

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.9+0.4+0.5+0.1+0.8

Next day

+1.7+2.4-0.7+1.1+0.6

+1.9+3.2-1.3+2.0-0.2

+2.8pendingpending+1.8+1.0

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue exceeded INR 5 billion, up 37% year on year and 15% sequentially. EBITDA rose 53% year on year and margin reached 32%. The second cartridge line doubled sterile production days, while the third awaits qualification. Management reaffirmed FY28 targets of USD 400 million revenue and USD 160 million EBITDA.

Likely market impact

Positive momentum and added capacity support the FY28 outlook, though line qualification, shipping delays and capacity ramp-up remain key risks.